These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 24746904)

  • 21. Serum 25-hydroxyvitamin D, non-alcoholic fatty liver disease and type 2 diabetes.
    Afarideh M; Ghajar A; Noshad S; Saadat M; Khajeh E; Esteghamati A
    Nutr Metab Cardiovasc Dis; 2017 Jan; 27(1):93-95. PubMed ID: 27986351
    [No Abstract]   [Full Text] [Related]  

  • 22. Predictive value of neutrophiltolymphocyte ratio in the severity of non-alcoholic fatty liver disease among type 2 diabetes patients.
    Kahraman NK; Kahraman C; Koçak FE; Coşgun S; Şanal B; Korkmaz M; Bayhan Z; Zeren S
    Acta Gastroenterol Belg; 2016; 79(3):295-300. PubMed ID: 27821024
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management and diagnosis of fatty liver disease.
    Schneier AT; Citti CC; Dieterich DT
    Expert Rev Gastroenterol Hepatol; 2015 May; 9(5):671-83. PubMed ID: 25716275
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Circulating periostin in patients with nonalcoholic fatty liver disease.
    Polyzos SA; Kountouras J; Anastasilakis AD; Papatheodorou A; Kokkoris P; Terpos E
    Endocrine; 2017 May; 56(2):438-441. PubMed ID: 27738886
    [No Abstract]   [Full Text] [Related]  

  • 25. Evolving Management Strategies for Nonalcoholic Fatty Liver Disease-Targeting Primary Care Physicians.
    Yadav Y; Syn WK; Basu R
    Diabetes Technol Ther; 2019 Nov; 21(11):611-618. PubMed ID: 31335197
    [No Abstract]   [Full Text] [Related]  

  • 26. Exercising in the COVID-19 era: implications in non-alcoholic fatty liver disease (NAFLD).
    O'Gorman P; Norris S
    BMJ Open Gastroenterol; 2021 Jun; 8(1):. PubMed ID: 34168043
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circulating dipeptidyl peptidase-4 activity correlates with measures of hepatocyte apoptosis and fibrosis in non-alcoholic fatty liver disease in type 2 diabetes mellitus and obesity: A dual cohort cross-sectional study.
    Williams KH; Vieira De Ribeiro AJ; Prakoso E; Veillard AS; Shackel NA; Brooks B; Bu Y; Cavanagh E; Raleigh J; McLennan SV; McCaughan GW; Keane FM; Zekry A; Gorrell MD; Twigg SM
    J Diabetes; 2015 Nov; 7(6):809-19. PubMed ID: 25350950
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Noninvasive diagnosis of nonalcoholic steatohepatitis: Emerging approaches.
    Pan Q; Fan JG
    Hepatobiliary Pancreat Dis Int; 2019 Feb; 18(1):1-3. PubMed ID: 30611667
    [No Abstract]   [Full Text] [Related]  

  • 29. Current complications and challenges in nonalcoholic steatohepatitis screening and diagnosis.
    Golabi P; Sayiner M; Fazel Y; Koenig A; Henry L; Younossi ZM
    Expert Rev Gastroenterol Hepatol; 2016; 10(1):63-71. PubMed ID: 26469309
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Non-alcoholic fatty liver in children and adolescents with excess weight and obesity].
    Guijarro de Armas MG; Monereo Megías S; Navea Aguilera C; Merino Viveros M; Vega Piñero MB
    Med Clin (Barc); 2015 Jan; 144(2):55-8. PubMed ID: 24768200
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma: A Growing Epidemic?
    Yopp AC; Choti MA
    Dig Dis; 2015 Sep; 33(5):642-7. PubMed ID: 26398208
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Non-alcoholic fatty liver disease in obese adults: clinical aspects and current management strategies.
    Pallayova M; Taheri S
    Clin Obes; 2014 Oct; 4(5):243-53. PubMed ID: 25825857
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Managing non-alcoholic fatty liver disease in diabetes: Challenges and opportunities.
    Lee CH; Lam KS
    J Diabetes Investig; 2017 Mar; 8(2):131-133. PubMed ID: 27181498
    [No Abstract]   [Full Text] [Related]  

  • 34. [Fatty liver: frequent and not completely harmless].
    Lang C; Georgi A; Gubler C
    Praxis (Bern 1994); 2013 Sep; 102(18):1089-101. PubMed ID: 24005067
    [No Abstract]   [Full Text] [Related]  

  • 35. Role of diet and nutritional management in non-alcoholic fatty liver disease.
    Fan JG; Cao HX
    J Gastroenterol Hepatol; 2013 Dec; 28 Suppl 4():81-7. PubMed ID: 24251710
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Editorial: screening for NAFLD - a promising strategy to mitigate future burden of liver disease.
    Sinha R; Lockman KA
    Aliment Pharmacol Ther; 2016 Jan; 43(1):163. PubMed ID: 26638929
    [No Abstract]   [Full Text] [Related]  

  • 37. Document on a comprehensive approach to type 2 diabetes mellitus.
    Reyes-García R; Moreno-Pérez Ó; Tejera-Pérez C; Fernández-García D; Bellido-Castañeda V; de la Torre Casares ML; Rozas-Moreno P; Fernández-García JC; Marco Martínez A; Escalada-San Martín J; Gargallo-Fernández M; Botana-López M; López-Fernández J; González-Clemente JM; Jódar-Gimeno E; Mezquita-Raya P;
    Endocrinol Diabetes Nutr (Engl Ed); 2019; 66(7):443-458. PubMed ID: 30827909
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Utility of noninvasive methods for the characterization of nonalcoholic liver steatosis in the family practice. The "VARES" Italian multicenter study.
    Grattagliano I; Ubaldi E; Napoli L; Marulli CF; Nebiacolombo C; Cottone C; Portincasa P
    Ann Hepatol; 2013; 12(1):70-7. PubMed ID: 23293196
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Noninvasive diagnosis of fatty liver disease].
    Qu Y; Lu LG
    Zhonghua Gan Zang Bing Za Zhi; 2010 Feb; 18(2):155-7. PubMed ID: 20196962
    [No Abstract]   [Full Text] [Related]  

  • 40. Assessment of inflammation and fibrosis in non-alcoholic fatty liver disease by imaging-based techniques.
    Cobbold JF; Patel D; Taylor-Robinson SD
    J Gastroenterol Hepatol; 2012 Aug; 27(8):1281-92. PubMed ID: 22432836
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.